Compare KVHI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | CRBU |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.2M | 145.8M |
| IPO Year | 1996 | 2021 |
| Metric | KVHI | CRBU |
|---|---|---|
| Price | $9.33 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 210.4K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 3.64 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $9,622,000.00 | N/A |
| Revenue This Year | $28.90 | $1.63 |
| Revenue Next Year | $31.85 | $10.93 |
| P/E Ratio | $309.00 | ★ N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $1.38 |
| 52 Week High | $13.00 | $3.53 |
| Indicator | KVHI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 31.38 |
| Support Level | $8.72 | $1.39 |
| Resistance Level | $9.41 | $1.77 |
| Average True Range (ATR) | 0.41 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 68.23 | 3.80 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.